Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.41 |
| ▸ | TK1 | P04183 | 2/20 | 0.40 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 5/20 | 0.40 |
| ▸ | PPARA | Q07869 | 5/20 | 0.40 |
| ▸ | PPARD | Q03181 | 3/20 | 0.40 |
| ▸ | DUT | P33316 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23215123 | 1.00 | KIF11 (0.41) | KIF11KCNN4TK1SRRPPARG | |
| SCHEMBL23215125 | 1.00 | KIF11 (0.41) | KIF11KCNN4TK1SRRPPARG | |
| Lithium Ion SCHEMBL29745408 | 0.89 | TK1 (0.38) | KIF11KCNN4TK1SRRPPARG | |
| Lithium Ion SCHEMBL29745334 | 0.89 | TK1 (0.38) | KIF11KCNN4TK1SRRPPARG | |
| SCHEMBL29745562 | 0.87 | KMT2A (0.42) | KIF11KCNN4TK1DUTCES1 | |
| SCHEMBL29745219 | 0.87 | KMT2A (0.42) | KIF11KCNN4TK1DUTCES1 | |
| SCHEMBL9365526 | 0.79 | KIF11 (0.43) | KIF11KCNN4TK1DUTCYP2C19 | |
| SCHEMBL9365537 | 0.79 | KIF11 (0.43) | KIF11KCNN4TK1DUTCYP2C19 | |
| SCHEMBL23215946 | 0.77 | TK1 (0.45) | KIF11KCNN4TK1DUTCYP2C19 | |
| SCHEMBL4794864 | 0.77 | TK1 (0.45) | KIF11KCNN4TK1DUTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2021071806-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNH3 | KIF11 519/4885KCNN4 53/4885TK1 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.